4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-014914
CHIEF FINANCIAL OFFICER sold 4,250 shares at an average $23.18 ($98,530)
- CHIEF FINANCIAL OFFICER acquired 4,250 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hohl Benjamin · CHIEF FINANCIAL OFFICER
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-05-28 | Exercise or conversion : show line 1 in the form 10b5-1 | +4,250 | $2.48 | $10,540 | 4,250 | D |
| 2024-05-28 | Sale : show line 2 in the form 10b5-1 | −1,906 | $22.89 | $43,628 | 2,344 | D |
| 2024-05-28 | Sale : show line 3 in the form 10b5-1 | −2,334 | $23.42 | $54,659 | 10 | D |
| 2024-05-28 | Sale : show line 4 in the form 10b5-1 | −10 | $24.34 | $243 | 0 | D |
| Open-market sales · 4,250 sh · avg $23.18 · $98,530 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-05-28 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (right to buy) | −4,250 | 216,870 | D |
Loading xslF345X05/form4-05302024_090558.xml…